Navigation Links
CorMatrix(R) ECM(TM) Receives CE Mark for Cardiac Tissue Repair

ATLANTA, June 15 /PRNewswire/ -- CorMatrix® Cardiovascular, a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today it has received CE mark for its CorMatrix ECM for Cardiac Tissue Repair. With this designation, CorMatrix is now able to market this product in European Union countries.

"This CE mark will allow surgeons in Europe to expand their use of CorMatrix ECM to patients needing cardiac tissue repair," said Beecher Lewis, President and Chief Operating Officer, CorMatrix. "We believe this additional indication will allow us to significantly expand our presence outside of the United States and drive growth in key markets."

CorMatrix's ECM for Cardiac Tissue Repair is used to repair heart structures during open heart surgery – such as closing a hole in the heart (known as atrial septal defect or ASD). During surgery, CorMatrix ECM is sutured onto the heart tissue in need of repair. It then serves as a scaffold, enabling the body's own cells to infiltrate and ultimately replace and remodel the implanted ECM with native tissue. The anatomy is restored naturally through the course of the body's innate wound healing process. It works differently than other available surgical materials, as CorMatrix ECM allows for repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can result in unwanted effects.

"Through my experience using CorMatrix ECM for pericardial closure procedures, we've seen that it supports native tissue repair and provides favorable outcomes for patients," said Prof. Giovanni Stellin, Chief pediatric cardiac surgeon at the University of Padova. "The cardiac tissue repair product will be a welcome addition to our surgical protocol."

Surgeons attending the International Society for Minimally Invasive Cardiovascular Surgery (ISMICS) meeting in Berlin, June 16-19, 2010, may hear more about CorMatrix ECM by visiting booth #6293 or during two poster presentations featuring CorMatrix ECM Technology on Thursday, June 17.

CorMatrix ECM Technology has been commercially available in the U.S. since 2006 and has been implanted in nearly 20,000 cardiac surgery procedures at more than 300 hospitals in the U.S.

About CorMatrix ECM Technology

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark for its ECM Technology as an implant for pericardial closure and for use in cardiac tissue repair.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative cardiovascular devices that harness the body's innate ability to remodel damaged tissue. For more information, visit

SOURCE CorMatrix Cardiovascular, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
2. CorMatrix Announces Publication of Pre-Clinical Data in Journal of American College of Cardiology (JACC) Demonstrating the Role of CorMatrix ECM(TM) Technology in Remodeling Cardiac Tissue
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
(Date:11/25/2015)... 2015 On Tuesday, November 24, 2015, ... against Wright Medical Technology, Inc. for product liability ... hip implant device, awarded $11 million in favor ... trial and three days of deliberations, the jury ... defectively designed and unreasonably dangerous, and that Wright ...
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
Breaking Medicine Technology:
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... ... 25, 2015 , ... In honor of Pulmonary Hypertension Awareness ... groups responsible for advancing care for pulmonary hypertension (PH) patients and helping to ... will receive special recognition throughout 2016 as part of PHA’s 25th anniversary celebrations. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Many people ... fatigue, fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who find ... diet and exercise regimen instead of their thyroid, especially if they don’t have any ...
Breaking Medicine News(10 mins):